Evommune, Inc. (NYSE:EVMN) Receives Consensus Recommendation of “Buy” from Analysts

Evommune, Inc. (NYSE:EVMN) has been given a consensus recommendation of “Buy” by the fourteen analysts that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, nine have assigned a buy recommendation and three have given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $49.25.

Several equities research analysts recently issued reports on EVMN shares. Oppenheimer started coverage on shares of Evommune in a research note on Tuesday, April 7th. They issued an “outperform” rating and a $50.00 target price for the company. Wall Street Zen upgraded shares of Evommune from a “sell” rating to a “hold” rating in a research note on Sunday, May 10th. Evercore reiterated an “outperform” rating and issued a $55.00 target price on shares of Evommune in a research note on Tuesday, February 10th. Stifel Nicolaus began coverage on shares of Evommune in a research note on Friday, May 1st. They issued a “buy” rating and a $54.00 target price for the company. Finally, Weiss Ratings began coverage on shares of Evommune in a report on Tuesday, February 3rd. They issued a “sell (e)” rating on the stock.

Evommune Price Performance

Shares of NYSE:EVMN opened at $23.01 on Monday. Evommune has a 52-week low of $13.89 and a 52-week high of $33.20. The firm has a market cap of $828.86 million and a P/E ratio of -2.42. The firm has a 50-day moving average price of $24.14.

Evommune (NYSE:EVMN) last issued its earnings results on Thursday, May 7th. The company reported ($0.64) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.83) by $0.19. Equities research analysts anticipate that Evommune will post -2.83 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of EVMN. China Universal Asset Management Co. Ltd. bought a new position in Evommune in the 4th quarter valued at about $34,000. Strs Ohio bought a new position in Evommune in the 1st quarter valued at about $41,000. The Manufacturers Life Insurance Company bought a new position in Evommune in the 4th quarter valued at about $179,000. XTX Topco Ltd bought a new position in Evommune in the 4th quarter valued at about $321,000. Finally, Oxford Asset Management LLP bought a new position in Evommune in the 4th quarter valued at about $335,000.

Evommune Company Profile

Evommune is a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria (“CSU”), atopic dermatitis (“AD”) and ulcerative colitis (“UC”). Chronic inflammation is a significant healthcare problem in the world, substantially impacting patients’ quality of life and leading to life-threatening conditions. These conditions, if not prevented, ultimately lead to fatal diseases, such as cardiovascular diseases, diabetes and cancer, which contribute to three out of every five deaths worldwide and result in an estimated $90 billion of annual cost to the healthcare system in the United States.